Platelet activation may limit the response to tissue-type plasminogen activator (t-PA) during coronary thrombolysis in humans. As an index of platelet activation, we assessed thromboxane A2 biosynthesis during coronary thrombolysis with intravenous t-PA in patients with acute myocardial infarction. Urinary 2,3-dinor-thromboxane B2, a metabolite of thromboxane A2, was increased to a peak of 3,327+±511 pg/mg creatinine (n=12) following administration of intravenous t-PA and remained elevated for 48 hours. This increase was abolished by pretreatment with aspirin 325 mg orally (n=6), indicating de novo biosynthesis of thromboxane A2 rather than washout of preformed metabolites during reperfusion. Prostacyclin (PGI2) biosynthesis, determined by excretion of 2,3-dinor-6-keto-PGFia, also increased after t-PA administration. However, this increase was less pronounced in patients who reperfused (28+±3.3 ng.hr/mg creatinine) than in patients who failed to reperfuse (118+±30 ng-hr/mg creatinine, p<0.05). These data provide evidence of platelet activation during coronary thrombolysis with t-PA. In patients who reperfuse, the reduction in PGI2 biosynthesis may be a marker of reperfusion injury to the vasculature and may further amplify platelet activation. (Circulation 1989;80:1718-1725 P latelet activation plays a major role in limiting the response to tissue-type plasminogen activator (t-PA) in experimental models of coronary thrombosis.1-4 In particular, platelets delay reperfusion and induce reocclusion.1,4 Platelet activation is also increased in patients with acute myocardial infarction treated with intravenous streptokinase,5 and antiplatelet therapy enhances the response to streptokinase, accelerating reperfusion6 and further reducing mortality.7 However, streptokinase directly activates human platelets.5 In contrast, t-PA inhibits platelet function in vitro.8 Although t-PA has been reported to increase platelet aggregation ex vivo,9 this increase may reflect an 
P latelet activation plays a major role in limiting the response to tissue-type plasminogen activator (t-PA) in experimental models of coronary thrombosis. [1] [2] [3] [4] In particular, platelets delay reperfusion and induce reocclusion.1,4 Platelet activation is also increased in patients with acute myocardial infarction treated with intravenous streptokinase,5 and antiplatelet therapy enhances the response to streptokinase, accelerating reperfusion6 and further reducing mortality.7 However, streptokinase directly activates human platelets.5 In contrast, t-PA inhibits platelet function in vitro.8 Although t-PA has been reported to increase platelet aggregation ex vivo,9 this increase may reflect an artifact due to plasminogen activation enhanced by fibrin formed during sampling10 and a proaggregatory response to plasmin."1 Whether platelet activation also occurs in vivo during coronary thrombolysis induced by t-PA is unknown. In addition, there is little information on what regulates platelet activation in this setting.
In the present study we examined thromboxane (Tx) A2 biosynthesis as an index of platelet activation during coronary thrombolysis with t-PA in humans. TxA2, the major cyclo-oxygenase product of arachidonic acid derived from platelets, is formed by platelets on activation and amplifies the platelet aggregation and release response to many agonists. 12 We also determined biosynthesis of prostacyclin (PGI2), a major cyclo-oxygenase product of arachidonic acid in endothelium and a potent platelet inhibitor.13 Formation of these eicosanoids is increased in conditions associated with platelet activation, including unstable angina, acute myocardial infarction,14 and severe peripheral vascular disease,15 which is consistent with the hypothesis that they regulate platelet function in vivo.
Methods

Study Protocol
The study group consisted of patients admitted with chest pain of cardiac origin of less than 4 hours duration who had electrocardiographic evidence of an acute myocardial infarction. Patients were excluded if they had taken aspirin or any other cyclo-oxygenase inhibitor in the 10 days before admission. All patients gave written, informed consent. t-PA (Genentech, South San Francisco, California) was administered intravenously as a 7-mg bolus followed by a continuous infusion of 53 mg over the first hour, 20 mg over the second hour, and then 10 mg/hr over the subsequent 2 hours.
Biosynthesis of TxA2 and PGI was determined as urinary excretion of their enzymatic metabolites, 2,3 -dinor-TxB2 and 2,3-dinor-6-keto-prostaglandin (PG) Fia, respectively. Urine was collected over 4 hours after the administration of t-PA and every 6 hours thereafter for 48 hours. Urine was also collected for 24 hours on day 5. In addition, where possible, a spot urine sample was obtained immediately before t-PA administration. Plasma creatine phosphokinase (CPK) was measured at 6-hour intervals over the first 24 hours and then every 12 hours. Fibrinogen was determined before initiation of t-PA infusion and 2 hours after its discontinuation. Platelet counts were determined before t-PA and also in the 24 hours after t-PA administration.
In addition to t-PA, heparin 1,000 units/hr was administered intravenously 90 minutes after initiation of the t-PA infusion and adjusted to maintain the cephalin kaolin time at twice control. All patients received prophylactic lidocaine given as a bolus dose of 3 mg/kg followed by an infusion of 1.75 mg/kg/hr, sublingual nitrates, and morphine 3 Urine was also obtained from a group of patients with unstable angina admitted over the same period. Unstable angina was defined as at least one episode of chest pain, typical of ischemia, occurring at rest and lasting for 15 minutes or more. All patients were admitted into the study within 24 hours of their last episode of chest pain, and all were demonstrated to have coronary artery disease on subsequent coronary angiography. These patients received intravenous nitrates and heparin as described for the patients receiving t-PA. In addition, data from patients receiving thrombolytic therapy were compared with previously published data from a group of patients with acute myocardial infarction who did not receive thrombolytic therapy.14 These patients had been well characterized and had been studied according to the same protocol, other than not receiving t-PA. Distribution of the infarcts and clinical course were similar in the two groups.
Aspirin-Treated Patients
To address the origin of the thromboxane metabolites, 325 mg aspirin were administered orally at the time of admission immediately before the administration of t-PA in six additional patients. The clinical features, site of infarction, and peak plasma CPK were similar to those treated with t-PA alone.
Biochemical Studies
Urine was analyzed for 2,3-dinor-TxB2 and 2,3-dinor-6-keto-PGF,,a by gas chromatography and negative-ion chemical ionization mass spectrometry, as previously described.20,21 For 2,3-dinorTxB2, 1 ng/ml tetradeuterated 2,3-dinor-TxB2 was added to 3 ml urine. After initial formation of the methoxime derivative, the samples were selectively extracted by passage through bonded-phase, phenylboronic acid columns and then subjected to thin-layer chromatography (TLC). After the formation of the pentafluorobenzyl ester and further TLC, the trimethylsilylether derivative was formed. Quantitative analysis was performed on a NERMAG 10-lOC mass spectrometer operating in the negativeion mode coupled with a Varian Vista 6000 gas chromatograph, monitoring m/z 586 for endogenous 2,3 -dinor-TxB2 and m/z 590 for the tetradeuterated internal standard.
2,3 -Dinor-6-keto-PGFia was determined in a 3 -ml urine sample after the addition of 1 ng/ml tetradeuterated 2,3-dinor-6-keto-PGF1a as internal standard. After selective extraction under acidic and alkaline conditions, as previously described,21 the methoxime derivative was formed. After further purification by TLC, the pentafluorobenzyl ester was formed and the sample finally derivatized to the trimethylsilylether. Quantitation was performed as for 2,3-dinor-TxB2 with selective ion monitoring at m/z 586 and m/z 590 for the endogenous 2,3-dinor-6-keto-PGFia and the tetradeuterated internal standard, respectively. relations were performed between plasma CPK and urinary metabolites for the different groups. These analyses are nonparametric and, therefore, make no assumptions about the distribution of the data.23
Results
Twelve patients (11 men, one woman) received t-PA alone (Table 1 ). An additional six patients (five men, one woman) received aspirin immediately before t-PA. Medications before admission included calcium channel blockers in two and f8-blockers in three patients. One patient received nifedipine 10 mg s.l. on admission. t-PA was administered 128+13 minutes (range, 40-240 minutes) from the onset of chest pain. Eight of the patients who did not receive aspirin had an early rise in plasma CPK with a peak CPK at 6.1+0.1 hours from the onset of t-PA infusion. Coronary arteriography was performed in seven of these patients, and all had patent infarctrelated vessels. In four patients peak CPK occurred at 18.3+2.3 hours. Two of these patients had coronary angiography, and both were found to have an occluded infarct-related artery. Five of the six patients treated with aspirin had an early rise in plasma CPK (Table 1) . Three of these patients underwent cardiac catheterization, and all had patent infarct-related coronary arteries. The sixth aspirintreated patient had a late rise in plasma CPK and had an occluded vessel at angiography.
Fibrinogen decreased from 297±+24 mg/dl on admission to 160±14 mg/dl 2 hours after discontinuation of t-PA (p<0.01). The platelet count declined from 290±14 x103/u1l to 248+12 x103/ l after t-PA (p<O.05). After t-PA one patient developed a groin hematoma and another marked hematuria. A third developed hypotension requiring treatment with dobutamine.
Urinary 2,3 -dinor-TxB2 was markedly elevated in the first urine collection after t-PA administration (2,584±463 pg/mg creatinine; normal, <350 pg/mg creatinine) and rose to a peak of 3,327±511 pg/mg creatinine within 10 hours of t-PA (Figure 1 Figure 1 ).
Excretion of 2,3-dinor-6-keto-PGF,,, (normal, <220 pg/mg creatinine) also increased in patients treated with t-PA alone (Figures 2 and 3 ). However, this increase was less in patients who reperfused. in the patients receiving t-PA than we have previously reported in acute myocardial infarction. In patients with acute myocardial infarction who did ( not receive thrombolytic therapy. urinary 2.3-6-keto-PGF,a . dinor-TxB2 was only modestly elevated on admisand plasma . sion and showed no further increase during a comt-PA admin-. parable 48-hour time period.5 '4 In contrast, in two d; wg, patients . patients in whom urine was obtained before t-PA ents dhe 95% . administration, 2,3-dinor-TxB2 excretion, similar ed group of ...on admission to those of untreated patients, ic therapy.'74 . increased after t-PA. While comparisons with a historical group and with unstable angina must be viewed with caution and the latter group does not serve as a control for the effect of t-PA, they natic metab-. support the hypothesis that TxA2 biosynthesis he kidney. 31 .increases after the administration of t-PA to an rine avoids ...extent that may be functionally important. easurement ...The increase in TxA formation provides eviplasma and . dence that platelet activity is increased during cor- This study also demonstrates that patients who reperfuse with t-PA fail to show the normal infarctrelated rise in PGI2 biosynthesis, as determined by excretion of its enzymatic metabolite, 2,3-dinor-6-keto-PGFia. In patients with acute myocardial infarction who are not receiving a thrombolytic agent, PGI2 formation rose over the 48 hours after admission and gradually declined toward normal by day 5.5,14,40 This activity correlated closely with plasma CPK level, and striking increases occurred in patients with large myocardial infarctions, findings that suggest that the increase in PG12 biosynthesis derives from the heart.14,41 The cellular origin is uncertain, but it is probably vascular endothelium because isolated myocardial cells have no prostaglandin synthase activity and endothelial cells are the major source of PGI2 in myocardial tissue.42 Furthermore, injured myocytes release arachidonic acid,43 which may be metabolized by other cells to form prostaglandins including PGI2. 44 Although the number of patients was small, a similar increase in PGI2 was seen in patients who failed to reperfuse after t-PA administration. In contrast, the increase in PGI2 biosynthesis was blunted in patients who reperfused, and it did not correlate with plasma CPK. The normal prolonged increase in PGI2 biosynthesis also fails to occur following reperfusion with streptokinase.5 The mechanism of the reduction in PGI2 biosynthesis after coronary reperfusion is uncertain. Reperfusion may reduce infarct size and, as a consequence, PGI2 biosynthesis. However, because CPK release correlates with infarct size, even in the setting of reperfusion,45-47 there would continue to be a relation between plasma CPK and PGI2 formation. In contrast, no correlation was found between these variables after reperfusion with t-PA. An alternative explanation is that the decrease in PGI2 formation reflects reperfusion injury of the coronary artery. In canine experiments, reperfusion of the ischemic vascular bed results in histologic and functional evidence of endothelial injury. 48 Recent studies in vitro suggest that this may be mediated by oxygen free radicals generated during reperfusion and reoxygenation of the ischemic endothelium.49'50 Thus, the failure to increase PGI2 biosynthesis after reperfusion with t-PA may be due to reperfusion injury of the vascular endothelium in the area of infarction.
What induces platelet activation during coronary thrombolysis with t-PA is uncertain. Experimental studies suggest that the coronary bed is the major may be activated at the site of thrombolysis by plasmin10, 51, 52 This increase suggests that PGI2 may regulate platelet activity at the platelet-vessel wall interface.
Inhibition of vascular cyclo-oxygenase increases platelet deposition in vivo, which is consistent with this hypothesis.62'63 Thus, the loss of PGI2 formation may allow platelet adhesion and subsequent aggregation to occur in the reperfused vascular bed.
While these studies provide evidence for platelet activation during coronary thrombolysis, the combined use of platelet inhibition and thrombolytic agents must be viewed with caution. Preliminary data suggest that the risk of hemorrhage during coronary thrombolysis is increased in patients with prolonged bleeding times.64 While the ISIS-I1 trial showed no increased risk of bleeding when aspirin was combined with streptokinase, more potent platelet inhibitors may increase this risk.
In conclusion, platelet activation is increased during coronary thrombolysis with t-PA in humans. These data are consistent with studies in experimental models demonstrating that platelets limit the thrombolytic response to t-PA. A possible mediator of platelet activation during coronary thrombolysis with t-PA is TxA2 because biosynthesis of this eicosanoid is increased. In addition, these data demonstrate a reduction in PGI2 biosynthesis in patients who reperfuse. This may be a noninvasive marker of reperfusion injury in humans and may amplify further platelet activation during coronary thrombolysis. These data support the further evaluation of antiplatelet therapy and TxA2 inhibition during coronary thrombolysis with t-PA.
